- Home
- AMC vs GPCR Comparison
AMC vs GPCR Comparison
Compare AMC & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMC
- GPCR
- Stock Information
- Founded
- AMC 1920
- GPCR 2016
- Country
- AMC United States
- GPCR United States
- Employees
- AMC N/A
- GPCR N/A
- Industry
- AMC Movies/Entertainment
- GPCR
- Sector
- AMC Consumer Discretionary
- GPCR
- Exchange
- AMC Nasdaq
- GPCR Nasdaq
- Market Cap
- AMC 1.3B
- GPCR 1.2B
- IPO Year
- AMC 2013
- GPCR 2023
- Fundamental
- Price
- AMC $2.93
- GPCR $24.36
- Analyst Decision
- AMC Hold
- GPCR Strong Buy
- Analyst Count
- AMC 7
- GPCR 9
- Target Price
- AMC $3.94
- GPCR $75.63
- AVG Volume (30 Days)
- AMC 12.3M
- GPCR 1.2M
- Earning Date
- AMC 11-05-2025
- GPCR 11-12-2025
- Dividend Yield
- AMC N/A
- GPCR N/A
- EPS Growth
- AMC N/A
- GPCR N/A
- EPS
- AMC N/A
- GPCR N/A
- Revenue
- AMC $4,915,600,000.00
- GPCR N/A
- Revenue This Year
- AMC $7.93
- GPCR N/A
- Revenue Next Year
- AMC $6.63
- GPCR N/A
- P/E Ratio
- AMC N/A
- GPCR N/A
- Revenue Growth
- AMC 9.42
- GPCR N/A
- 52 Week Low
- AMC $2.45
- GPCR $13.22
- 52 Week High
- AMC $5.56
- GPCR $45.37
- Technical
- Relative Strength Index (RSI)
- AMC 53.02
- GPCR 69.97
- Support Level
- AMC $2.75
- GPCR $20.04
- Resistance Level
- AMC $3.08
- GPCR $25.06
- Average True Range (ATR)
- AMC 0.10
- GPCR 1.30
- MACD
- AMC 0.03
- GPCR 0.35
- Stochastic Oscillator
- AMC 61.54
- GPCR 89.03
About AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. It owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.